Introduction
The interest on "early Spondyloarthtiris (SpA)" (eSpA) is born in the last ten years for the acknowledgment of the "evidence based" utility of the rapid diagnostic and therapeutic approach in these diseases. In particular, the diffusion of the new imaging techniques such as Ultrasound (US) and Magnetic resonance (MRI) and the possibilities to use antiTNFalpha treatments as efficacies strategies to stop clinical and radiological progression, have deeply changed our point of view of the mission in rheumatology.
In the first 10 years of disease, the axial and peripheral damages might be deeply modified with antiTNFalpha treatment 1 . After this first window of opportunity, the clinical efficacy of the therapy dramatically decreased.
Unfortunately, the diagnostic delay (DD) is still very high 2 with important consequence on radiological damage (New York score for sacroiliitis and bamboo spine).
Furthermore, since the phases of the disease, the disease might have severe outcomes on quality of life of patients in terms of depression and anxiety 3 .
The aim of this review was to discuss the concept, role of new imaging techniques, therapeutic opportunities and research agenda of early spondyloarthritis.
Method
We firstly discussed the definition of eSpA: the chronological cut off, the concept of undifferentiated SpA (uSpa), the new ASAS classification criteria, the role of new imaging techniques in diagnosis (Ultrasound 
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. In 2010, the update of ASAS/EULAR showed that every expert agreed that in the pre-radiographic (axial) eSpA, with MRI sacroiliac bone oedema, the management recommendations of SpA, included antiTNFalpha, should be equally extend 11 .
Definition of eSpa
Otherwise, it's also recognized that not all patients with axial eSpA will necessary develop structural radiological damage changes, comprised in criteria for AS 12,13 and, in a part of patients might be a provisional diagnosis that should be confirmed.
Only De Miguel and D'Agostino 4,5 proposed a two years of follow up to define the eSpA diagnosis, but this definitions was not validated in literature and included in guidelines of the disease 11 .
Role of new imaging techniques (MRI and US)

MRI
In early disease, the use of MRI as a diagnostic tool is a very important step because it can reveal preradiographic disease. There are four MRI findings of active (acute) sacroiliitis associated with axial SpAosteitis/bone marrow oedema, enthesitis, capsulitis, and synovitis.
However, the ASAS consensus included only the presence of bone marrow oedema (Figure 1 ) on STIR sequences and osteitis on the T1 weighted gadolinium as the fundamental feature of sacroiliitis 9 .
Even if STIR sequences at MRI (T2 with fat suppression) might be considered sufficient for early diagnosis to detect bone oedema, in doubt cases, the use of gadolinium (T1 with fat suppression and contrast) seemed more useful to better enhance hyperintensity of signal and to show the increase of perfusion of bone (osteitis) 9 .
Otherwise, ASAS committee did not include other active signs of sacroiliitis as synovitis, enthesitis and capsulitis in diagnostic criteria, that probably should be better studied in the future to understand its potential role in early diagnosis 9 .
Chronic structural lesions (bone marrow fat deposition, erosions, sclerosis, ankylosis) have until now an uncertain diagnostic significance; in particular, fat accumulation and erosions might be deeply studied in the future to understand if they might be interpreted as inflammatory and as severity signs, respectively.
In fact, in the Puhakka14 and Weber15 studies, in eSpA patients, erosions were found in 80% and 50% respectively.
Furthermore, in the first issue, sclerosis and fat deposition were present in 71% and 63% of cases14. Probably, the structural damage of the SIJ, not detect by x-ray, might be revealed by MRI, in very early disease, but the exact significance of this datum and its weight on the diagnosis and chose of treatments was not investigated.
US
-US of SIJ Ultrasound (US) is a routine procedure for joint evaluation 16, 17, 18 and periarticular ligaments 18 of SIJ evaluation in SpA.
The SIJ effusion in SpA were previously studied by Spadaro et al. 16 and Bandinelli 18 Otherwise, Klauser demonstrated that the contrast enhanced colour Doppler US of SIJ is a predictor of active sacroiliitis at MRI 17 , but more studies might be conducted to confirm this datum to clearly define its role in early diagnosis. Nevertheless, so far very few papers on US evaluation of the SIJ have been published, overall on tendons assessment, even though it has been well demonstrated that pathological changes could be detected with this diagnostic tool.
In particular, interestingly, Bandinelli et al. in 23 early SpA demonstrated that sacrotuberosus ligament thickness was higher than in controls but a larger cohort of patients might be studied in the future to confirm the importance of ligaments evaluation in eSpA 18 .
-US of entheses and the concept "sub clinical" and "occult enthesitis" in eSpa In 2011, De Miguel et al. found a high sensitivity (53.1%) and specificity (83.3%) of entheses US in 113 early SpA 4 compared to non inflammatory controls and other rheumatic disease.
In the same year, D'Agostino et al., demonstrated in a prospective study on 118 eSpA, that Power Doppler US (PDUS) had a good predictive value of (sensitivity 76.5% and specificity 81.3%) for diagnosis of definitive Spa but did correlate with ASAS criteria. This datum confirmed that a limit of these criteria is not to include entheseal evaluation as one of the most important features for diagnosis, but probably the presence of numerous scores in literature with not an univocal technique represent until now a great difficulty to a great diffusion of US of entheses in daily practice and its standardization 19 .
Furthermore, enthesitis might be often under-diagnosed and showed in early phase by clinical examination only in a small percentage, as Bandinelli et al. 8 showed in 92 ePsA patients (Figure 2 ). In fact, in this study, US showed in high percentage entheseal abnormalities independent from clinical examination and rheumatologic symptoms. The most relevant findings revealed by US were thickness and PDUS signal of entheses, probably due to the oedema, increase of vessels and cell infiltration, respectively, described by Mc Gonagle in initial phase of SpA 20 , even if until now a direct comparison between US and histological data was never performed in humans. Interestingly, other recent studies showed the presence of "occult" entheseal abnormalities in psoriasis 21, 22, 23 and in inflammatory bowel disease (IBD) 24 , without signs and symptoms of SpA and without correlation with the activity indices of disease neither of psoriasis neither of bowel.
Actually, there is not a clear definition of this "iceberg disease" and we did not know if might be a disease continuum with eSpA and if these occult abnormalities might have a role on the chose of disease modifying treatments for comorbilities (such severe psoriasis or IBD).
Treatment
The 2011 international recommendation (with the interview of 1246 rheumatologists of 18 countries) suggested the use of antiTNFalpha also in preradiographic axial disease diagnosed with ASAS criteria (expert agreement of 86%) 11 . Otherwise, there is still now not a clear definition on the right moment to start a disease modifying treatment in early disease.
Only Scarpa in 2008 conducted a study on effect of traditional DMARDs in eSpa: 35 ePsA treated for six months with low dosage of methotrexate (10 mg weekly) were followed up with routine clinical and laboratory examination 25 .
The he use of other DMARDs (such salazopyrin and leflunomide) was not investigated. Only the antiTNF were evaluated in large clinical trials and seemed to be able to determine both clinical and instrumental remission, with impressive effect of bone oedema and osteitis at MRI evaluation in the early phase of disease 26, 27 
